Wen Zeng1, Fankai Meng1, Zeming Liu2, Xia Mao3, Li Luo3, Miao Zheng1, Shuang Qin1, Wenli Liu1, Jianfeng Zhou1, Hanying Sun1, Lifang Huang1. 1. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China. 2. Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, China. 3. Laboratory of Hematolody, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China.
Abstract
OBJECTIVE: To investigate the relationship between the Bcl-2 and survivin expression and the different regimens therapeutic efficacy newly diagnosed multiple myeloma (NDMM). METHODS: We retrospectively assessed the association of Bcl-2 and survivin expression with chemotherapeutic efficacy and prognosis in 59 NDMM patients in a single center. RESULTS: The positive expression rate for survivin and Bcl-2 was 35% and 74%, respectively. Survivin and Bcl-2 protein expression were not associated with clinical stage, suggesting that they are not related to tumor burden in NDMM. Bortezomib-based regimens were more effective in reducing tumor burden and achieving therapeutic (complete and partial) response compared with non-bortezomib-based regimens irrespective of Bcl-2 or survivin expression (P < 0.05). In cases with both negative Bcl-2 and survivin expression (Bcl-2(-)survivin(-)), the response to bortezomib and non-bortezomib-based regimens was similar (p = 0.429). Bcl-2 and survivin expression were not correlated with overall survival (OS); however, Bcl-2-survivin- cases showed a trend towards a longer OS (P = 0.078). CONCLUSION: We recommend bortezomib-containing regimens for NDMM with single or double-positive Bcl-2 and survivin expression.
OBJECTIVE: To investigate the relationship between the Bcl-2 and survivin expression and the different regimens therapeutic efficacy newly diagnosed multiple myeloma (NDMM). METHODS: We retrospectively assessed the association of Bcl-2 and survivin expression with chemotherapeutic efficacy and prognosis in 59 NDMM patients in a single center. RESULTS: The positive expression rate for survivin and Bcl-2 was 35% and 74%, respectively. Survivin and Bcl-2 protein expression were not associated with clinical stage, suggesting that they are not related to tumor burden in NDMM. Bortezomib-based regimens were more effective in reducing tumor burden and achieving therapeutic (complete and partial) response compared with non-bortezomib-based regimens irrespective of Bcl-2 or survivin expression (P < 0.05). In cases with both negative Bcl-2 and survivin expression (Bcl-2(-)survivin(-)), the response to bortezomib and non-bortezomib-based regimens was similar (p = 0.429). Bcl-2 and survivin expression were not correlated with overall survival (OS); however, Bcl-2-survivin- cases showed a trend towards a longer OS (P = 0.078). CONCLUSION: We recommend bortezomib-containing regimens for NDMM with single or double-positive Bcl-2 and survivin expression.
Authors: Bing Z Carter; Yihua Qiu; Xuelin Huang; Lixia Diao; Nianxiang Zhang; Kevin R Coombes; Duncan H Mak; Marina Konopleva; Jorge Cortes; Hagop M Kantarjian; Gordon B Mills; Michael Andreeff; Steven M Kornblau Journal: Blood Date: 2012-05-29 Impact factor: 22.113
Authors: O Markovic; D Marisavljevic; V Cemerikic-Martinovic; T Martinovic; B Filipovic; D Stanisavljevic; R Zivković; J Hajder; N Stanisavljevic; B Mihaljevic Journal: Med Oncol Date: 2012-04-13 Impact factor: 3.064
Authors: Bruce D Cheson; Nancy L Bartlett; Julie M Vose; Andres Lopez-Hernandez; Amanda L Seiz; Anne T Keating; Setareh Shamsili; Kyriakos P Papadopoulos Journal: Cancer Date: 2011-10-17 Impact factor: 6.921
Authors: Jade K Pollock; Lisa M Greene; Seema M Nathwani; Paula Kinsella; Niamh M O'Boyle; Mary J Meegan; Daniela M Zisterer Journal: Invest New Drugs Date: 2018-02-19 Impact factor: 3.850